Cabazitaxel
| Title | Journal |
|---|---|
| Molecular alterations and emerging targets in castration resistant prostate cancer. | European journal of cancer (Oxford, England : 1990) 20140301 |
| Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20130415 |
| Management of docetaxel failures in metastatic castrate-resistant prostate cancer. | The Urologic clinics of North America 20121101 |
| Metastatic castrate-resistant prostate cancer: dawn of a new age of management. | BJU international 20121001 |
| A new era for castrate resistant prostate cancer: a treatment review and update. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20120901 |
| Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. | BJU international 20120901 |
| Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report. | Clinical genitourinary cancer 20120901 |
| Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. | Cancer biology & therapy 20120901 |
| Novel and bone-targeted agents for CRPC. | Annals of oncology : official journal of the European Society for Medical Oncology 20120901 |
| Management of advanced prostate cancer in senior adults: the new landscape. | The oncologist 20120901 |
| Cabazitaxel in metastatic castration-resistant prostate cancer. | Expert review of anticancer therapy 20120901 |
| New treatment options for patients with metastatic castration-resistant prostate cancer. | Cancer treatment reviews 20120801 |
| Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC). | BJU international 20120801 |
| Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer. | P & T : a peer-reviewed journal for formulary management 20120801 |
| Managing side effects of the novel taxane cabazitaxel in castrate-resistant prostate cancer. | Clinical journal of oncology nursing 20120601 |
| NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. | The Lancet. Oncology 20120601 |
| Novel molecular targets for the therapy of castration-resistant prostate cancer. | European urology 20120501 |
| Cabazitaxel for prostate cancer: patient preparation and ongoing care. | British journal of nursing (Mark Allen Publishing) 20120501 |
| The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use. | The oncologist 20120401 |
| Castration-resistant prostate cancer: systemic therapy in 2012. | Clinics (Sao Paulo, Brazil) 20120401 |
| [Second line therapy for castration-resistant prostate cancer (CRPC)]. | Der Urologe. Ausg. A 20120301 |
| Advances in the management of high-risk localised and metastatic prostate cancer. | BJU international 20120301 |
| Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies. | BJU international 20120301 |
| [Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients]. | Der Urologe. Ausg. A 20120301 |
| Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific binding. | Journal of pharmaceutical and biomedical analysis 20120205 |
| [Promising on advanced cancer, several new drugs coming]. | Lakartidningen 20120201 |
| Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches. | Oncology (Williston Park, N.Y.) 20120101 |
| Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling. | Case reports in oncology 20120101 |
| [Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France]. | Bulletin du cancer 20120101 |
| Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatment. | Clinical genitourinary cancer 20111201 |
| Novel therapies for metastatic castrate-resistant prostate cancer. | Journal of the National Cancer Institute 20111116 |
| Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. | The oncologist 20111101 |
| Recent advances in the therapy of castration-resistant prostate cancer: the price of progress. | Maturitas 20111001 |
| Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. | Asian journal of andrology 20110901 |
| Abiraterone and increased survival in metastatic prostate cancer. | The New England journal of medicine 20110825 |
| New treatment options for castrate-resistant prostate cancer: a urology perspective. | The Canadian journal of urology 20110801 |
| Cabazitaxel: a novel microtubule inhibitor. | Drugs 20110709 |
| Overcoming chemotherapy resistance in prostate cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110615 |
| Optimal management of bone metastases in prostate cancer. | Current oncology reports 20110601 |
| Current clinical trials in castrate-resistant prostate cancer. | Current urology reports 20110601 |
| [The trend toward development of novel agents based on the mechanism of prostate cancer progression]. | Nihon rinsho. Japanese journal of clinical medicine 20110601 |
| [Jevtana: clinically significant improvement in survival of patients previously treated with docetaxel]. | Revue medicale suisse 20110525 |
| A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. | European journal of cancer (Oxford, England : 1990) 20110501 |
| Contemporary management of metastatic castration-resistant prostate cancer. | Current opinion in urology 20110501 |
| Cabazitaxel for the treatment of prostate cancer. | Expert opinion on pharmacotherapy 20110401 |
| TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. | Future oncology (London, England) 20110401 |
| Cabazitaxel: a new drug for metastatic prostate cancer. | Asian journal of andrology 20110301 |
| Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions. | Anti-cancer agents in medicinal chemistry 20110301 |
| [Castration resistant prostate cancer 2011]. | Aktuelle Urologie 20110301 |
| Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. | Maturitas 20110201 |
| New options for the management of castration-resistant prostate cancer: a case perspective. | Journal of the National Comprehensive Cancer Network : JNCCN 20110201 |
| Cabazitaxel for castration-resistant prostate cancer. | Lancet (London, England) 20110108 |
| Cabazitaxel for castration-resistant prostate cancer. | Lancet (London, England) 20110108 |
| Cabazitaxel for the treatment of castration-resistant prostate cancer. | Future oncology (London, England) 20110101 |
| Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. | Drug design, development and therapy 20110101 |
| Cabazitaxel: filling one of the gaps in the treatment of prostate cancer. | Cancer biology & therapy 20101215 |
| Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer. | Clinical genitourinary cancer 20101201 |
| A renaissance in the medical treatment of advanced prostate cancer. | Oncology (Williston Park, N.Y.) 20101201 |
| Cabazitaxel in prostate cancer: stretching a string. | Lancet (London, England) 20101002 |
| Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. | Lancet (London, England) 20101002 |
| Cabazitaxel, a new taxane with favorable properties. | Drugs of today (Barcelona, Spain : 1998) 20101001 |
| Cabazitaxel, a taxane for men with hormone-refractory metastatic prostate cancer. | Oncology (Williston Park, N.Y.) 20101001 |
| New treatments for metastic prostate cancer. | The Medical letter on drugs and therapeutics 20100906 |
| Cabazitaxel. | Nature reviews. Drug discovery 20100901 |
| New taxane treats advanced prostate cancer. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100801 |
| Castration refractory prostate cancer: cinderella finally comes to the ball. | Onkologie 20100101 |
| Critical appraisal of cabazitaxel in the management of advanced prostate cancer. | Clinical interventions in aging 20100101 |